TABLE OF CONTENTS

WELCOME LETTER 5

CANCER DRUG DEVELOPMENT FORUM (CDDF) 6

ORGANISING PARTNERS 7

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME) 7

CONFERENCE COMMITTEE 7

PROGRAMME AT A GLANCE 9

SCIENTIFIC PROGRAMME 10

POSTERS 15

EXHIBITION FLOOR PLAN 17

ACKNOWLEDGEMENT 18

GENERAL INFORMATION 19

SATELLITE SYMPOSIA 22
WELCOME LETTER

Welcome to the second edition of the Immunotherapy of Cancer Conference (ITOC-2).

This meeting is growing rapidly into a global platform for translational research in the field of immuno-oncology. Organized by the Cancer Drug Development Forum, whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development, the ITOC conference series aims to provide a forum for discussion of early clinical drug development and address its unique challenges.

For this second edition, the conference again has surpassed our expectations in terms of attendance and participants. Our excellent scientific programme with an international faculty will focus on many topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T-cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.

This week will offer you a broad and exciting range of opportunities and tools to have exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC-2 in the beautiful city of Munich. In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome, therefore we encourage you to complete the evaluation form after the conference and please do not hesitate to reach out to our team onsite or via info@itoc-conference.eu.

Yours sincerely

Professor Volkmar Nüssler
Conference President

Professor Heinz Zwierzina
Scientific Chair
ORGANISING PARTNERS

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

An application for accreditation has been submitted to the European Accreditation Council for CME (EACCME) of the European Union of Medical Specialists (UEMS). The Accreditation Council of Oncology in Europe (ACOE), in partnership with the UEMSEACCME, will review and evaluate the event on the basis of the UEMS-EACCME quality criteria.

CONFERENCE COMMITTEE

Conference Presidents
- Alexander M.M. Eggermont (France)
- Volkmar Nüssler (Germany)
- Mario Sznol (United States)

Scientific Committee
- Heinz Zwierzina (Austria) - Scientific Programme Committee Chair
- Paolo A. Ascierto (Italy)
- Lisa H. Butterfield (United States)
- Angus Dalglish (United Kingdom)
- Stefan Endres (Germany)
- Bernard A. Fox (United States)
- Leif Hakansson (Sweden)
- Jens Hasskarl (Switzerland)
- Robert Hawkins (United Kingdom)
- Volker Heinemann (Germany)
- Samir Khleif (United States)
- Pedro Romero (Switzerland)
- Jose Saro (Switzerland)
- Wenru Song (China)
- Jean Viallet (United States)
- Verena Voelter (Switzerland)

Abstract Review Committee
- Volkmar Nüssler (Germany) – Abstract Chair
- Sebastian Kobold (Germany)
- Robert Hawkins (United Kingdom)
- Angus Dalglish (United Kingdom)
<table>
<thead>
<tr>
<th>TIME</th>
<th>TUESDAY, 24 MARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>10:30</td>
<td>OPENING KEYNOTE AND PLENARY SESSION 1 Immune suppression and microenvironment</td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30</td>
<td>SATELLITE SYMPOSIUM Cancer immunotherapy: translating innovative science into clinical trials</td>
</tr>
<tr>
<td>14:30</td>
<td>PLENARY SESSION 1 (CONTINUED): Immune suppression and microenvironment</td>
</tr>
<tr>
<td>16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>18:00</td>
<td>Welcome Reception and Poster viewing</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>PLENARY SESSION 4 Immunomodulatory agents</td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>PLENARY SESSION 7 Adoptive T-Cell Therapy</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>PLENARY SESSION 8 Engineered T cell Therapy</td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00</td>
<td>SATELLITE SYMPOSIUM CARs and Cell Therapy: Today and the Road Ahead</td>
</tr>
<tr>
<td>14:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME

WEDNESDAY, 25 MARCH

10:30  INTRODUCTION
Heinz Zwierzina, Innsbruck University, Austria

10:45  KEYNOTE LECTURE: COMBINING IMMUNOMODULATORY AND/OR TARGETED AGENTS
Alexander Eggermont, Institut Gustav Roussy, France

11:10  PLENARY SESSION 1: IMMUNE SUPPRESSION AND MICROENVIRONMENT
Chairs: Alexander Eggermont and Heinz Zwierzina

- INTRATUMORAL HETEROGENEITY OF IMMUNOCOMPETENT CELLS
  Marco Gerlinger, Institute of Cancer Research, United Kingdom

- RELATIONSHIP BETWEEN MUTATIONAL DENSITY AND RESPONSE TO IMMUNOTHERAPY
  Timothy Chan, Memorial Sloan Kettering Cancer Center, USA

- IN VIVO DISCOVERY OF IMMUNOTHERAPY TARGETS IN THE TUMOR ENVIRONMENT
  Kai Wucherpfennig, Dana-Farber Cancer Institute, USA

12:30 LUNCH

13:30  SATELLITE SYMPOSIUM: CANCER IMMUNOTHERAPY: TRANSLATING INNOVATIVE SCIENCE INTO CLINICAL TRIALS

14:30  PLENARY SESSION 1 (CONTINUED): IMMUNE SUPPRESSION AND MICROENVIRONMENT
Chairs: Mario Sznol and Samir Khleif

- THE ROLE OF AN INFLAMMATORY MICROENVIRONMENT FOR MELANOMA METASTASIS AND THERAPY RESISTANCE
  Thomas Tüting, Bonn University, Germany

- ROLE OF EXOSOMES IN IMMUNE SUPPRESSION
  Licia Rivoltini, IRCCS, Italy

- ANTI-TUMOUR RESPONSE BY RADIOThERAPY
  Philipp Beckhove, Heidelberg University, Germany

- PROFFERED PAPER: ROLE OF SIGNAL TRANSDUCTION AND MICRORNAS ON THE IMMUNOGENICITY OF MELANOMA CELLS
  Barbara Seliger, Martin Luther University Halle-Wittenberg, Germany

- PROFFERED PAPER: IMAGING IN CANCER IMMUNOLOGY: PHENOTYPING OF MULTIPLE IMMUNE CELL SUBSETS IN-SITU IN FFPE TISSUE SECTIONS
  Bjoern Wendik, Germany

16:00 COFFEE BREAK
16:30  **PLENARY SESSION 2 : CHECKPOINT INHIBITION**  
Chairs: Pedro Romero and Wenru Song  

**THERAPY OF ADVANCED CANCER BASED ON IMMUNE CHECKPOINT BLOCKADE**  
Mario Sznol, Yale Cancer Center, USA

**PD-L1 AS A MARKER FOR RESPONSIVENESS TO PD-1/PD-L1 BLOCKADE**  
Janis Taube, Johns Hopkins University, USA

**ROLE OF CHECKPOINT INHIBITORS IN HEMATOLOGIC MALIGNANCIES**  
Willemin Hobo, Radboud University, Netherlands

**PROFFERED PAPER: IDENTIFICATION OF SECOND-GENERATION POTENT AND SELECTIVE INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE-1 (IDO1)**  
Juan Jaen, USA

**PROFFERED PAPER: A NEW FUSION RECEPTOR OVERCOMES PD-1-MEDIATED IMMUNOSUPPRESSION IN ADOPTIVE T CELL THERAPY**  
Sebastian Kobold, Klinikum Der Ludwig-Maximilians University, Germany

18:10 -19:00  **WELCOME RECEPTION AND POSTER VIEWING**

---

**THURSDAY, 26 MARCH**

09:00  **PLENARY SESSION 3 : COMBINATION THERAPY**  
Chairs: Bernie Fox and Volker Heinemann  

**RATIONALE FOR COMBINATION STRATEGY IN IMMUNOTHERAPY**  
Pedro Romero, Ludwig Center for Cancer Research, Switzerland

**COMBINATION OF ANTI-CANCER VACCINES AND CHECKPOINT INHIBITORS**  
Samir Khleif, GRU Cancer Center, USA

**COMBINATION OF CHECKPOINT INHIBITORS WITH ANTI-ANGIOGENIC AGENTS**  
Hans Joerg Hammers, Johns Hopkins University, USA

**SEQUENCING OR COMBINATION APPROACHES IN IMMUNOTHERAPY**  
Paolo Ascierto, National Tumor Institute Fondazione Naples, Italy

**PROFFERED PAPER: VIROTHERAPY OVERCOMES TUMOR RESISTANCE TO PD1-IMMUNOTHERAPY BY BROAD MUTANOME-DIRECTED T CELL RESPONSES**  
Woller Norman, Hannover Medical School, Germany

10:35  **COFFEE BREAK**

11:00  **PLENARY SESSION 4 : IMMUNOMODULATORY AGENTS**  
Chair: Paolo Ascierto  

**RATIONALE OF INTEGRATING IMIDS INTO CANCER IMMUNOTHERAPY APPROACHES**  
Angus Dalglish, St George's University of London, United Kingdom

**IMMUNOMODULATION AND THE ROLE OF THE MICROENVIRONMENT IN LYMPHOMA**  
Alan Ramsay, Kings College, United Kingdom
CEA TCB: A NOVEL T-CELL BISPECIFIC ANTIBODY FOR THE TREATMENT OF SOLID TUMORS
Marina Bacac, Roche-Glycart, Switzerland

PROFFERED PAPER: IMMUNOMODULATORY CHARACTERISTICS OF RESMINOSTAT, A NOVEL HDAC INHIBITOR IN PHASE II CLINICAL DEVELOPMENT
Svetlana Hamm, Germany

12:15 LUNCH BREAK

13:00 SATELLITE SYMPOSIUM: BROADENING THE HORIZON OF IMMUNO-ONCOLOGY IN 2015: MELANOIMA, LUNG CANCER AND BEYOND

14:00 PLENARY SESSION 5: ANTI-CANCER VACCINES
Chairs: Angus Dalgleish and George Coukos

IMPROVING CANCER VACCINE EFFICACY: WHAT IS NEEDED?
Denise Nardelli-Haefliger, Lausanne University Hospital, Switzerland

MANIPULATIONS OF THE TUMOR MICROENVIRONMENT BY DENDRITIC CELL VACCINES
Carl Figdor, Radboud University, Netherlands

PROFFERED PAPER: PROLONGED SURVIVAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WHO ARE TREATED WITH TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS
Marnix Bosch, USA

PROFFERED PAPER: A METHOD FOR DEVELOPING PREDICTIVE TESTS FOR IMMUNOTHERAPY BENEFIT
Heinrich Roder, USA

15:10 COFFEE BREAK

15:30 PLENARY SESSION 6: MONITORING OF IMMUNOTHERAPY
Chairs: Lisa Butterfield and Leif Hakansson

UNEXPECTED TREG, MDSC AND CYTOKINE RESPONSES
Lisa Butterfield, University of Pittsburgh, USA

RECRUITMENT OF INFLAMMATORY CELLS TO TUMOURS – IMPORTANCE OF VASCULAR ENDOTHELium MODULATION
George Coukos, Ludwig University, Switzerland

T CELL THERAPY OF MELANOMA; WHAT WE GIVE AND WHAT WE GET!
Per thor Straten, Centre for Cancer Immunotherapy, Denmark

EVALUATION OF TIL IN BREAST CANCER: CURRENT PERSPECTIVE
Bohuslav Melichar, Palacký University Medical School & Teaching Hospital, Czech Republic

16:50 – 18:00 POSTER VIEWING
FRIDAY, 27 MARCH

08:00  SATELLITE SYMPOSIUM: CHECKPOINT INHIBITION: TRANSFORMING BREAKTHROUGH SCIENCE INTO BETTER PATIENT CARE

09:00  PLENARY SESSION 7: ADOPTIVE T-CELL THERAPY
   Chairs: Carl Figdor and Per Thor Straten
   IDENTIFICATION OF TUMOR SPECIFIC TIL BY EXOME AND T CELL RECEPTOR SEQUENCING
   Jim Yang, NCI, USA
   POTENTIAL ROLE OF NKT CELLS IN ADOPTIVE CELL THERAPY
   Mark Exley, University Manchester, United Kingdom
   PREDICTORS OF TIL EFFICACY IN MELANOMA
   Michal Besser, Sheba Medical Center, Israel
   COMBINATION OF CHECKPOINT INHIBITORS AND CELL THERAPY
   Jeff Webber, Moffit Cancer Centre, USA

10:30  COFFEE BREAK

11:00  PLENARY SESSION 8: ENGINEERED T CELL THERAPY
   Chairs: Robert Hawkins and Jim Yang
   KEYNOTE LECTURE: CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS FOR CANCER IMMUNOTHERAPY
   Marcela Maus, University of Pennsylvania, USA
   SOLID TUMOURS
   Ulf Petrausch, USZ Zürich, Switzerland
   TARGET IDENTIFICATION AND VALIDATION
   Dominique Bonnet, Cancer Research UK, United Kingdom
   A PLATFORM COMBINING THE WORLD OF BITES AND CARS
   Michael Bachmann, Helmholtz-Zentrum Dresden, Germany

12:30  LUNCH

13:00  SATELLITE SYMPOSIUM: CARS AND CELL THERAPY – TODAY AND THE ROAD AHEAD

14:00  AWARDS CEREMONY AND CLOSING REMARKS
POSTERS

Posters are on display in the pavilion throughout the conference. Poster abstracts and author details are listed in the ITOC-2 Abstract Supplement.

MICROENVIRONMENT AND INFLAMMATION

ITOC2 - 001 Influence of tumor cell – fibroblast co-culture on monocyte differentiation and tumor growth in pancreatic cancer

ITOC2 - 002 Immunosuppressive microenvironment in pancreatic adenocarcinoma

ITOC2 - 003 Store-operated calcium signaling in EGF-mediated COX-2 inflammatory gene activation in cancer cells

ITOC2 - 005 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections

ITOC2 - 006 Humanized mouse models for preclinical testing of antitumor immune therapy

ITOC2 - 007 Notch triggers myeloid reprogramming in murine pancreatic cancer

IMMUNOSUPPRESSION

ITOC2 - 008 Two immune faces of pancreatic adenocarcinoma: Impact of immunosuppression

ITOC2 - 009 Melanoma differentiation-associated protein 5 (MDA5)-based tumor immunotherapy reprograms M2/G2-polarized myeloid-derived suppressor cells (MDSCs)

ITOC2 - 010 Role of signal transduction and miRNA on the immunogenicity of melanoma cells

THERAPEUTIC MODULATION OF IMMUNE CHECKPOINTS

ITOC2 - 011 Virotherapy overcomes tumor resistance to PD1-immunotherapy by broad mutanome-directed T cell responses

ITOC2 - 012 Identification of Second-Generation Potent and Selective Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1) for the Treatment of Cancer

ITOC2 - 013 Neoadjuvant immune checkpoint blockade for pancreatic cancer prevents local tumor recurrence through tissue resident antitumoral CD8+ CD103+ T cells

ITOC2 - 014 In vitro kynurenine modulation by novel dual-acting and selective TDO and IDO inhibitors

ITOC2 - 015 Immunomodulation of blasts in AML-Patients (PTS) with clinically approved response modifiers to improve antileukemic T-cell reactivity: An ex vivo simulation of the clinical

ITOC2 - 016 Therapy of hepatocellular carcinoma (HCC) with immunostimulatory RNA activating RIG-I

ANTI-CANCER VACCINES

ITOC2 - 017 Effective vaccination against melanoma in an animal study: Combination of laser-assisted dermal skin delivery and cross-presenting XCR1+ dermal DCs targeting

ITOC2 - 018 Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells

ITOC2 - 019 Hyperthermia induced immunogenic cell-death
<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITOC2 - 020</strong></td>
<td>An open-label multicenter phase II trial of aviscumine in previously treated patients with unresectable stage IV metastatic melanoma</td>
</tr>
<tr>
<td><strong>ITOC2 - 021</strong></td>
<td>VGX-3100 Immunotherapy for CIN2/3 Induces Regression of Cervical Lesions and Viral Clearance (Phase II Study): Implications for Treatment of HPV Associated Cancers</td>
</tr>
<tr>
<td><strong>ITOC2 - 022</strong></td>
<td>The melanoma immune-peptidome for T-cell-based anti-tumor immunotherapies</td>
</tr>
<tr>
<td><strong>ITOC2 - 023</strong></td>
<td>Vaccination with next-generation dendritic cells for AML postremission therapy induces antigen-specific T cell responses</td>
</tr>
<tr>
<td><strong>ITOC2 - 024</strong></td>
<td>Integrated computational pipeline for development of personalised melanoma vaccine</td>
</tr>
</tbody>
</table>

**ANTIBODY THERAPY**

<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITOC2 - 025</strong></td>
<td>Selective lysis of biphenotypic leukemia cells is mediated by dual-targeting triplebody 33-3-19 treatment</td>
</tr>
</tbody>
</table>

**ENGINEERED T-CELL THERAPY**

<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITOC2 - 027</strong></td>
<td>A new fusion receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy</td>
</tr>
<tr>
<td><strong>ITOC2 - 028</strong></td>
<td>Redirecting adenovirus-specific T cells by a tumor-specific T cell receptor for therapy of hepatocellular carcinoma</td>
</tr>
<tr>
<td><strong>ITOC2 - 029</strong></td>
<td>Transgenic antigen-specific, allogeneic HLA-A*0201-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity</td>
</tr>
</tbody>
</table>

**COMBINATION THERAPY**

<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITOC2 - 030</strong></td>
<td>Combination of CTLA4-blockade, depletion of CD25+ cells and active-specific immunotherapy prolongs survival in murine melanoma</td>
</tr>
<tr>
<td><strong>ITOC2 - 031</strong></td>
<td>Combination therapy identification of the neoantigen Ndufs1-V491A for investigations on immunotherapies in murine tumor models</td>
</tr>
<tr>
<td><strong>ITOC2 - 032</strong></td>
<td>Combination therapy Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development</td>
</tr>
<tr>
<td><strong>ITOC2 - 033</strong></td>
<td>Optimizing active-specific immunotherapy in lymphodepleted mice with subcutaneous melanoma</td>
</tr>
</tbody>
</table>

**MONITORING OF IMMUNOTHERAPY**

<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ITOC2 - 034</strong></td>
<td>Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma</td>
</tr>
<tr>
<td><strong>ITOC2 - 035</strong></td>
<td>Development of a 3D cell culture model for the investigation of cancer cell/immune cell interactions</td>
</tr>
<tr>
<td><strong>ITOC2 - 036</strong></td>
<td>The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients</td>
</tr>
<tr>
<td><strong>ITOC2 - 037</strong></td>
<td>A method for developing predictive tests for immunotherapy benefit</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENT

The conference is very grateful to the following companies for their generous support to ITOC-2

PLATINUM SPONSORS

Bristol-Myers Squibb

MERCK

Be well

NOVARTIS PHARMACEUTICALS

Roche

SILVER SPONSOR

Northwest Biotherapeutics

EDUCATIONAL GRANT

Celgene
GENERAL INFORMATION

SECRETARIAT

Cancer Drug Development Forum
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier, 83
B-1200 Brussels Belgium
Tel.: +32 (0) 2 775 02 01
Fax: +32 (0) 2 775 02 00 E

CONFERENCE VENUE

Hörsaal A (Auditorium A)
Klinikum Rechts der Isar
Entrance Einstein Strasse
TU Munich Ismaninger Str. 22
81675 Munich

HOW TO GET TO THE VENUE

The Klinikum Rechts der Isar is very accessible by public transport. From the Hilton Munich City (ITOC-2 official hotel), take tram 16 from tram stop Am Gasteig in the direction of Max-Weber-Platz.

The Klinikum is also reachable by Ubahn U4 and U5 – station Max-Weber-Platz.

Please note that the best entrance of the conference is not the Klinikum main entrance on Ismaniger Strasse. The conference is best accessed via the entrance on the Einstein Strasse, as indicated below.
Registration
ITOCS-2 is open to all registered participants. Your official delegate name badge is required for admission to the conference centre and all conference events. For security reasons, participants are requested to wear their badge at all times.

Registration Opening Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Opening Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEDNESDAY, 25 MARCH</td>
<td>8:00 - 18:00</td>
</tr>
<tr>
<td>THURSDAY, 26 MARCH</td>
<td>8:00 - 18:00</td>
</tr>
<tr>
<td>FRIDAY, 27 MARCH</td>
<td>8:00 - 11:00</td>
</tr>
</tbody>
</table>

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>FULL CONGRESS</th>
<th>ONE DAY CONGRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADEMIA REGISTRATION</td>
<td>600 €</td>
<td>175 €</td>
</tr>
<tr>
<td>INDUSTRY REGISTRATION</td>
<td>850 €</td>
<td>275 €</td>
</tr>
<tr>
<td>STUDENT REGISTRATION*</td>
<td>175 €</td>
<td></td>
</tr>
</tbody>
</table>

*appropriate and valid student identification has to be provided

Badges
For security reasons, delegates are requested to wear their badge at all times during the conference. Delegates having lost their badge can obtain a new badge at the registration desk. A replacement fee may be charged.

Lost & Found
All enquiries should be directed to the registration desk in the entrance hall. The organisers accept no responsibility for loss due to theft or negligence.

Catering
Coffee breaks, lunches and a welcome reception courtesy of the organisers have been scheduled and are included in the registration fees. Exact times are listed in the programme overview.

Conference Bag
To receive the conference bag including all conference material, please present the voucher attached to your badge at the bag distribution centre, in the registration area.

Exhibition
The exhibition is held in the foyer of the conference centre. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

Insurance
The organisers of ITOC-2 do not accept liability for individual medical, travel or personal insurance. Participants are strongly recommended to obtain their own personal insurance policies. The organisers of ITOC-2 accept no responsibility for loss due to theft or negligence.

Language & Translation
The official language of the conference is English. No simultaneous translation is provided.

POLICIES
ITOCS-2 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC-2 Conference asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the conference centre they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC Conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.
SATELLITE SYMPOSIA

WEDNESDAY, 25 MARCH

13.30–14.30 CANCER IMMUNOTHERAPY: TRANSLATING INNOVATIVE SCIENCE INTO CLINICAL TRIALS

WELCOME
Prof. Dirk Jäger, Germany

THE INTERPLAY BETWEEN CANCER AND THE IMMUNE SYSTEM
Aurélien Marabelle, France

ADVANCES IN CANCER IMMUNOTHERAPY AND THE ROLE OF BIOMARKERS
Dr. Priti Hegde, USA

NEW CONSIDERATIONS IN CLINICAL TRIAL DESIGN
Prof. Dirk Jäger, Germany

PANEL DISCUSSION
All faculty

THURSDAY, 26 MARCH

13:00 – 14:00 BROADENING THE HORIZON OF IMMUNO-ONCOLOGY IN 2015: MELANOMA, LUNG CANCER AND BEYOND
Chair: Professor Christian Peschel (Munich, Germany)

IMMUNO-ONCOLOGY: RAISING THE BAR IN MELANOMA TREATMENT
Winald Gerritsen, Netherlands

NEW ERA OF THERAPY?
Peter Brossart, Germany

IMMUNO-ONCOLOGY: CHANGING THE LANDSCAPE OF CANCER THERAPY?
Peter Johnson, United Kingdom
FRIDAY, 27 MARCH

08:00 – 09:00 CHECKPOINT INHIBITION: TRANSFORMING BREAKTHROUGH SCIENCE INTO BETTER PATIENT CARE
Chair: Dirk Schadendorf, Germany

INTRODUCTION AND OPENING REMARKS
Dirk Schadendorf, Germany

CLINICAL INSIGHTS: CHECKPOINT INHIBITOR THERAPY ACROSS THE SPECTRUM OF ADVANCED MELANOMA
Dirk Schadendorf, Germany

CLINICAL INSIGHTS: NEW APPROACHES WITH CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED NSCLC
Rolf Stahel, Switzerland

PANEL DISCUSSION BASED ON CASE STUDY (2ND LINE PATIENT): HOW DO WE MOST EFFECTIVELY INTEGRATE ANTI-PD-1 THERAPIES INTO CLINICAL PRACTICE?
Faculty

CLOSING REMARKS

13:00 – 14:00 CARS AND CELL THERAPY: TODAY AND THE ROAD AHEAD

WELCOME AND INTRODUCTIONS
Marcela Maus, USA

THE DEVELOPMENT AND CLINICAL EXPERIENCE OF CTL019
Marcela Maus, USA

EOLVING CAR THERAPIES IN EUROPE
Hinrich Abken, Germany

CELL & GENE THERAPIES OF THE FUTURE: PRODUCTS IN DEVELOPMENT AT NOVARTIS
Mike Perry, USA

QUESTION AND ANSWER SESSION
The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria.

It was founded in 2001 as Biotherapy Development Association (BDA) and changed its name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organization breadth of interests.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can together exchange expertise to find the ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Learn more about CDDF at www.cddf.org.

Applicable for All Types of Solid Tumors
- DCVax-L for operable tumors
- DCVax-Direct for inoperable tumors

Targets Full Set of Tumor Biomarkers
- Impedes tumor escape

Substantial Patient Survival Extensions
- Long-term survivors in clinical trials to-date

Excellent Safety Profile
- Few SAEs in 10+ years of trials

Solid Manufacturing Infrastructure
- 3-5 Years of personalized doses in 8 days
- Stored and shipped frozen

DCVax® has not yet been approved for commercial distribution by the FDA or EMA.
Certainly we cannot treat all tumor types. But we are broadening the horizon of cancer treatment.

Immuno-Oncology by Bristol-Myers Squibb

---

**Thursday 26 March 2015, 13:00 – 14:00**

Klinikum rechts der Isar, TU Munich, Hörsaal A, Ismaniger Straße 22, 81675 Munich – Germany

**Broadening the horizon of Immuno-Oncology in 2015: Melanoma, lung cancer, and beyond**

*Chair: Christian Peschel (Munich, Germany)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:20</td>
<td>Immuno-Oncology: Raising the bar in melanoma treatment</td>
<td>Winald Gerritsen (Nijmegen, Netherlands)</td>
<td>Klinikum rechts der Isar, TU Munich, Hörsaal A, Ismaniger Straße 22, 81675 Munich – Germany</td>
</tr>
<tr>
<td>13:20 – 13:40</td>
<td>PD-1 inhibition in lung cancer: Paving the way for a brighter future</td>
<td>Peter Brossart (Bonn, Germany)</td>
<td>Klinikum rechts der Isar, TU Munich, Hörsaal A, Ismaniger Straße 22, 81675 Munich – Germany</td>
</tr>
<tr>
<td>13:40 – 14:00</td>
<td>Immuno-Oncology: Changing the landscape of cancer therapy?</td>
<td>Peter Johnson (Southampton, UK)</td>
<td>Klinikum rechts der Isar, TU Munich, Hörsaal A, Ismaniger Straße 22, 81675 Munich – Germany</td>
</tr>
</tbody>
</table>
CARs and Cell Therapy: Today and the Road Ahead

SAVE THE DATE:
Friday 27 March 2015
13:00-14:00

Hörsaal A, Klinikum rechts der Isar
TU Munich
Ismaninger Str. 22
81675 Munich – Germany

PROGRAM

13:00 – 13:05
Welcome
Marcela Maus, MD, PhD, Translational Research Program,
Abramson Cancer Center,
University of Pennsylvania, USA

13:05 – 13:20
The Development and Clinical Experience of CTL019
Marcela Maus, MD, PhD, Translational Research Program,
Abramson Cancer Center,
University of Pennsylvania, USA

13:20 – 13:35
Evolving CAR Therapies in Europe
Hirrich Abken, MD, Center for Molecular Medicine Cologne and
Department I for Internal Medicine,
University Hospital Cologne, Cologne, Germany

13:35 – 13:50
Cell & Gene Therapies of the Future: Novartis Portfolio
Michael S. Perry, DVM, PhD, FRCVS, Chief Scientific Officer,
Cell & Gene Therapy Unit,
Novartis Pharmaceuticals Corporation, USA

13:50 – 14:00
Q & A Panel Session

This program is supported by Novartis Cell and Gene Therapy Unit.
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.
Cancer immunotherapy: Translating innovative science into clinical trials

Wednesday 25 March 2015
13.30–14.30
Main auditorium
Technical University of Munich
Germany

Programme
Chair: Dirk Jäger, Heidelberg, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30–13.35</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>Dirk Jäger, Heidelberg, Germany</td>
</tr>
<tr>
<td>13.35–13.50</td>
<td>The interplay between cancer and the immune system</td>
</tr>
<tr>
<td></td>
<td>Aurélien Marabelle, Villejuif, France</td>
</tr>
<tr>
<td>13.50–14.00</td>
<td>Advances in cancer immunotherapy and the role of biomarkers</td>
</tr>
<tr>
<td></td>
<td>Priti Hegde, Genentech, USA</td>
</tr>
<tr>
<td>14.00–14.10</td>
<td>New considerations in clinical trial design</td>
</tr>
<tr>
<td></td>
<td>Dirk Jäger, Heidelberg, Germany</td>
</tr>
<tr>
<td>14.10–14.30</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td>All faculty</td>
</tr>
</tbody>
</table>

This presentation is not intended for physicians practising in the USA
Official ITOC-2 sponsored satellite symposium
Some tumor cells can evade the body’s immune response, which may result in disease progression\textsuperscript{2,3} 

- One function of the body’s immune response is to detect and destroy tumor cells through activated T cells and other mechanisms; tumor cells express multiple antigens that are not expressed in normal tissue.\textsuperscript{1-3}

- However, some tumor cells may evade the body’s immune response by exploiting the PD-1 checkpoint pathway through expression of the dual PD-1 ligands PD-L1 and PD-L2.\textsuperscript{1,2,4-7}

- PD-L1 and PD-L2 engage the PD-1 receptor on T cells in order to inactivate T cells, which may allow tumor cells to evade the immune response.\textsuperscript{1,2,8}

MSD is committed to furthering the understanding of immunology in cancer, including the role of the PD-1 pathway.

Visit the MSD booth to learn more.

PD-1=programmed cell death protein 1; PD-L1=programmed cell death ligand 1; PD-L2=programmed cell death ligand 2.


Copyright © 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. 5101-1128582-0002 05/15
The Cancer Drug Development Forum (CDDF) is pleased to welcome you to its 2nd ImmunoTherapy Of Cancer conference (ITOC-2)

JOIN US AT NEXT YEAR’S ITOC-3 !

Visit our websites at:
www.cddf.org
www.itoc-conference.eu

SAVE THE DATE
21 - 23 March 2016
MUNICH, GERMANY